BiondVax

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, August 11, 2023
GMP, Partnership, Asthma, Drug development, Table, Agility, University Medical Center, COVID-19, BVXV, Securities and Exchange Commission of Pakistan, Psoriasis, Public expenditure, VHH, CDMO, Animal, Laboratory, Max Planck, Security (finance), BiondVax, IBN, Pharmaceutical industry, Cryptocurrency

BiondVax’s unaudited financial results will be submitted to the Securities and Exchange Commission on Form 6‑K.

Key Points: 
  • BiondVax’s unaudited financial results will be submitted to the Securities and Exchange Commission on Form 6‑K.
  • As announced previously, BiondVax has decided to leverage its aseptic manufacturing site and laboratories by creating a CDMO business unit in parallel to its innovative R&D business unit.
  • BiondVax is pursuing a strategic partnership for its COVID-19 self-administered inhaled NanoAb therapeutic/prophylactic which demonstrated highly promising in vivo results in animals.
  • BiondVax holds exclusive options for exclusive licenses at pre agreed financial terms for each of the resulting NanoAbs.

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Retrieved on: 
Tuesday, August 1, 2023
Reichmann, Partnership, COVID-19, BVXV, Psoriasis, CDMO, Annual report, BiondVax, IBN, Pharmaceutical industry

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.

Key Points: 
  • JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.
  • As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.
  • “We are very pleased that Nasdaq has reviewed our plan and provided us the time to proceed with various initiatives already underway that alone or together will allow us to regain compliance with the shareholders’ equity listing requirement,” said Mr. Amir Reichman, BiondVax’s CEO.
  • Based on BiondVax’s plans, Nasdaq has provided an extension of time until October 30, 2023, for the company to demonstrate it has regained compliance.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
Monday, June 5, 2023
National Psoriasis Foundation, Psoriatic arthritis, Disease, Human, Asthma, Therapy, Macular degeneration, IBD, University Medical Center, Hook effect, Inflammation, Max Planck Society, COVID-19, Psoriasis, Interleukin 17, BVXV, COVID, Max Planck Institute for Multidisciplinary Sciences, IL-17A, Light, VHH, Patient, Patent, Hidradenitis suppurativa, MPG, UMG, Mab, Max Planck, Knowledge, Cytokine, Transport, BiondVax, Skin, Autoimmunity, Pharmaceutical industry, Vaccine

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Retrieved on: 
Monday, April 17, 2023
Exercise, SAB, Human, Drug development, Table, University Medical Center, Hook effect, Max Planck Society, COVID-19, CGMP, BVXV, GAAP, Associate, Psoriasis, VHH, CDMO, Patient, Organic compound, Annual report, Risk, Laboratory, Max Planck Institute for Multidisciplinary Sciences, MPG, IL-17, UMG, Immune system, Growth, Security (finance), Cytokine, EIB, BiondVax, Caregiver, Global Research Collaboration for Infectious Disease Preparedness, Cryptocurrency, Vaccine, Fine chemical, Pharmaceutical industry, VOC

At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission.

Key Points: 
  • At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission.
  • In addition, having access to a multi-asset pipeline would hedge BiondVax’s risk and provide greater opportunity and flexibility in pursuing partnering deals with other pharma companies.
  • As of December 31, 2022, BiondVax had cash and cash equivalents of $14 million as compared to $17.3 million as of December 31, 2021.
  • The complete audited financial results are available in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

BiondVax to Present at BIO-Europe Spring

Retrieved on: 
Thursday, March 16, 2023
BVXV, Communication, Psoriatic arthritis, Psoriasis, BiondVax, COVID-19, Asthma, Macular degeneration, Hook effect, Pharmaceutical industry

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd .

Key Points: 
  • JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd .
  • The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
  • Reichman and Joshua Phillipson, Director of Investor Relations and Communications, will be available to meet potential partners, collaborators, and investors.
  • To schedule a meeting with BiondVax register now at https://informaconnect.com/bioeurope-spring/ .

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

Retrieved on: 
Friday, March 3, 2023
Research, Patent, MBA, Pharmacology, Michael J. Freeman, IBN, Max Planck Society, Vaccine, IP, Mitsubishi Tanabe Pharma, BiondVax, The Michael J. Fox Foundation, Running, Humanitarian use licenses, III, Engineering, BVXV, Diagnosis, Biotechnology, Skin, Reichmann, Entrepreneurship, Interview, Pharmaceutical industry, Test

Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale.

Key Points: 
  • Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale.
  • The broadcast, hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency , is available for on-demand listening on Test.
  • To begin the interview, Reichman discussed his professional journey leading up to joining BiondVax in 2021.
  • That was a very nice start to my career as an entrepreneur… I didn’t stay with NeuroDerm until the exit.

BiondVax CEO Issues Letter to Shareholders

Retrieved on: 
Friday, December 30, 2022
PEI, Non-governmental organization, Infection, GMP, Neutralizing antibody, Drug development, BVXV, Failure, Macular degeneration, Contraindication, Max Planck, Pfizer, VHH, COVID-19, SARS-COV-2, Lead, Optimism, European Investment Bank, Risk, Comorbidity, Creativity, CDMO, Mab, MPI, Growth, Patient, Degenerative disease, Letter, Exercise, Collaboration, Omicron, Consultant, Paul Ehrlich Institute, Safety, Max Planck Society, Therapy, UMG, Psoriasis, BiondVax, EIB, Life, University Medical Center, Asthma, Library, Vaccine, Caregiver, Pharmaceutical industry, Risk management, Fine chemical

The letter reads as follows:

Key Points: 
  • The letter reads as follows:
    BiondVax’s 2022 achievements leave me incredibly optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders.
  • As compared to mAbs, NanoAbs being generated at MPI demonstrate several unique attributes such as greater binding affinity, stability at high temperatures, and formulation advantages.
  • We reported the successful first readout results in the preclinical in vivo study of our innovative inhaled COVID-19 NanoAb therapy.
  • I also want to thank our shareholders for their continued support as we progress toward our objectives.

BiondVax Announces Pricing of $8 Million Underwritten Public Offering

Retrieved on: 
Friday, December 16, 2022
BVXV, Coronavirus, Annual report, Degenerative disease, SEC filing, Security (finance), Sale, European Investment Bank, Prospectus, Telephone, Special-purpose acquisition company, Drug development, Risk, Research, BiondVax, COVID-19, ADS, Form, Pharmaceutical industry

The offering consists of 1,600,000 units and pre-funded units.

Key Points: 
  • The offering consists of 1,600,000 units and pre-funded units.
  • Each ADS represents 400 of our ordinary shares, no par value per share.
  • The offering is expected to close on December 20, 2022, subject to the satisfaction of customary closing conditions.
  • BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

Retrieved on: 
Tuesday, December 13, 2022
Asthma, BVXV, Weizmann Institute of Science, Degenerative disease, IBN, Glatiramer acetate, University Medical Center, Season, DBP, News, Knowledge, Drug Quality and Security Act, Psoriasis, Infection, Research, Teva Pharmaceuticals, History, Social media, Reichmann, COVID-19, Max Planck Society, Pharmaceutical industry, BiondVax

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.

Key Points: 
  • The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.
  • Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.
  • The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series .
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

BiondVax Regains Nasdaq Compliance

Retrieved on: 
Monday, December 12, 2022
BVXV, Coronavirus, Annual report, Degenerative disease, Communication, Security (finance), Drug development, Infection, BiondVax, Risk, COVID-19, Pharmaceutical industry

JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announces today the receipt of formal notifications from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity and minimum bid price.

Key Points: 
  • JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announces today the receipt of formal notifications from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity and minimum bid price.
  • Similarly, Nasdaq communicated to BiondVax that since the minimum bid price has now closed over $1.00 per share for the past ten trading days, the Company once again complies with Listing Rule 5550(a)(2).
  • Thus, Nasdaq has confirmed the Company now complies with Nasdaq Listing Rules and considers the abovementioned non-compliance matters to be closed.
  • BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases.